Basecare closes RMB150m Series C round led by Broad Vision Funds

Recently, Basecare , a company in the NGS market segment of reproduction, has raised 150 million yuan in a Series C financing round. This round of investment was led by Broad Vision Funds, with participation from Ming Bioventures and others.

Recently, Basecare , a company in the NGS market segment of reproduction, has raised 150 million yuan in a Series C financing round. This round of investment was led by Broad Vision Funds, with participation from Ming Bioventures and others.

Public record shows that Basecare focuses on the field of assisted reproduction and is a leading enterprise in the reproductive health segment. It operates four independent medical testing laboratories across China and has established 31 joint experiments with large medical institutions in various provinces and cities. The office has carried out business cooperation with more than 200 domestic medical institutions, and has carried out global business cooperation with many overseas institutions in countries such as Italy, Canada and Southeast Asia.

The PGS kit independently developed by Basecare was announced by the CFDA Medical Device Technology Evaluation Center in May 2016, becoming the first third-generation test tube baby test product in China to receive “Special Approval for Innovative Medical Devices”; it also obtained the first medical device registration certificate in the industry this year (National Machinery Standard: 20203400181).

The approval of the product filled the technical gap of the clinical application of the third-generation test tubes in China, marking the formal entry of the third-generation test tube PGS testing into the certified era and cementing Basecare’s monopoly position in this segment.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/19/basecare-closes-rmb150m-series-c-round-led-by-broad-vision-funds/.

Leave a Reply

Please Login to Comment